Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 125 versus LEVETIRACETAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 125 versus LEVETIRACETAM.
DILANTIN-125 vs LEVETIRACETAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Levetiracetam's precise mechanism of action is unknown. It binds to synaptic vesicle protein 2A (SV2A), which may modulate neurotransmitter release and reduce neuronal excitability. It also inhibits N-type calcium channels and reduces calcium influx, contributing to antiepileptic effects.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
500-1500 mg PO/IV BID; initial 500 mg BID, titrate by 500 mg BID every 2 weeks as tolerated; maximum 3000 mg/day.
None Documented
None Documented
Clinical Note
moderateLevetiracetam + Venlafaxine
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Venlafaxine."
Clinical Note
moderateLevetiracetam + Nefazodone
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Nefazodone."
Clinical Note
moderateLevetiracetam + Ranolazine
"The serum concentration of Ranolazine can be increased when it is combined with Levetiracetam."
Clinical Note
moderateLevetiracetam + Stiripentol
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
6–8 hours in adults; prolonged to 10–11 hours in mild-to-moderate renal impairment (CrCl 30–50 mL/min) and 16–24 hours in severe impairment (CrCl <30 mL/min); neonates up to 16 hours.
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Primarily renal (66% unchanged, 27% as inactive metabolite); minimal fecal (<2%).
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol."